PACIFIC EDGE LIMITED (PEB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PEB

PEB - PACIFIC EDGE LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.03
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.25

11 Jun
2026

-0.005

OPEN

$0.26

-1.96%

HIGH

$0.26

38,396

LOW

$0.25

OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-3.4
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx10.2 M
Book Value Per Share xxxxxxxxxxxxxxx0.9
Net Operating Cash Flow xxxxxxxxxxxxxxx-28.4 M
Net Profit Margin xxxxxxxxxxxxxxx-311.14 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-195.13 %
Return on Invested Capital xxxxxxxxxxxxxxx-188.29 %
Return on Assets xxxxxxxxxxxxxxx-131.60 %
Return on Equity xxxxxxxxxxxxxxx-195.13 %
Return on Total Capital xxxxxxxxxxxxxxx-185.29 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-28.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx6 M
Price To Book Value xxxxxxxxxxxxxxx16.70

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx1.15 %
Cost of Goods Sold xxxxxxxxxxxxxxx11 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx33 M
Research & Development xxxxxxxxxxxxxxx12 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

28/05/2026

3

Neutral

-

-

Jarden maintains a Neutral rating for Pacific Edge with its target price increased to NZ$0.20 from NZ$0.16 following an in-line FY26 financial result.

Global clinical test volumes declined by -16% relative to the prior corresponding period due to a Medicare non-coverage determination and downsized sales resources within the United States.

Operational metrics reflect growing commercial volume contributions from both the core payer mix and the targeted Triage platform alongside ongoing development of the high-fidelity Triage Plus asset.

Management targets an aggregate FY27 monthly cash burn ceiling of -NZ$2.5m, implying an annualised revenue milestone run rate exceeding NZ$17m based on current underlying fixed operating cost structures.

The upgraded valuation is driven by improved confidence surrounding long-term commercial test adoption forecasts alongside a reduced discount rate following steady progress on the draft local coverage determination, the broker notes.
Access Extra Coverage Research History >

PEB STOCK CHART

FNArena News on PEB

1
Australian Broker Call *Extra* Edition – May 28, 2026

May 28 2026 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – May 13, 2026

May 13 2026 - Daily Market Reports
3
July In Review: Energy And Banks Drive Gains

Aug 03 2023 - Australia
4
FNArena Corporate Results Monitor – 02-06-2023

Jun 02 2023 - Australia
5
Australian Broker Call *Extra* Edition – Jan 25, 2023

Jan 25 2023 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
2
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
3
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
4
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
5
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
6
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
7
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest
8
Tariff Uncertainty Negates ResMed’s Q1 Positives

Nov 05 2025 - Australia
9
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
10
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia